Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

OBJECTIVE: To evaluate the efficacy, safety, and tolerability of incremental doses of albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, administered with three dosing schedules in patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Reusch, Jane, Bush, Mark, Yang, Fred, Stewart, Murray
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752910/
https://www.ncbi.nlm.nih.gov/pubmed/19592625
http://dx.doi.org/10.2337/dc09-0366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752910/
https://www.ncbi.nlm.nih.gov/pubmed/19592625
http://dx.doi.org/10.2337/dc09-0366

Ejemplares similares